title: [Anti-inflammatory mechanism of qingfei xiaoyan wan studied with network pharmacology].
abstract: This study aims to clarify out the anti-inflammatory mechanism of Qingfei Xiaoyan Wan. Chemical constituents of Qingfei Xiaoyan Wan identified by UPLC Q-TOF, were submit to Molinspiration, PharmMapper and KEGG bioinformatics softwares for predicting their absorption parameters, target proteins and related pathways respectively; and the gene chip and real time-PCR were carried out to investigate the expression of inflammatory genes on lung tissue of guinea pigs or human bronchial epithelial cell lines. The predicted results showed that 19 of the 24 absorbable constituents affected at 9 inflammation-related pathways through 11 protein targets; Qingfei Xiaoyan Wan treatment can significantly reduce the infiltration of cytokines through ERK1 gene and 5 inflammatory pathways (Focal adhesion, Fc epsilon RI, Toll-like receptors, NK cell-mediated cytotoxic, and ERK/MAPK). The results of real time-PCR further confirmed that the anti-inflammatory effects of Qingfei Xiaoyan Wan were due to active ingredients such as arctigenin, cholic acid and sinapic acid intervened focal adhesion, Fc epsilon RI signaling and ERK/MAPK pathways. The novel approach of 'drug-target-pathway' will present an effective strategy for the study of traditional Chinese medicines.
authors.affiliation: College of Pharmacy, Nankai University, Tianjin 300071, China.
authors.forename: Bin-Feng
authors.initials: BF
authors.lastname: Cheng
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Hou
authors.forename: Min
authors.initials: M
authors.lastname: Jiang
authors.forename: Zhen-Ying
authors.initials: ZY
authors.lastname: Zhao
authors.forename: Lin-Yi
authors.initials: LY
authors.lastname: Dong
authors.forename: Gang
authors.initials: G
authors.lastname: Bai
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001249:Asthma / Q000378:metabolism* / Q000473:pathology; D002460:Cell Line; D019826:Cholic Acid / Q000494:pharmacology; D003373:Coumaric Acids / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism*; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004847:Epithelial Cells / Q000187:drug effects; D005260:Female; D005663:Furans / Q000494:pharmacology; D006168:Guinea Pigs; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D017705:Lignans / Q000494:pharmacology; D008168:Lung / Q000473:pathology; D020935:MAP Kinase Signaling System; D008297:Male; D011897:Random Allocation; D017455:Receptors, IgE / Q000378:metabolism; D051193:Toll-Like Receptors / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D003373:Coumaric Acids; D016207:Cytokines; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D005663:Furans; D017705:Lignans; D017455:Receptors, IgE; D051193:Toll-Like Receptors; C073734:sinapinic acid; D019826:Cholic Acid; C071942:arctigenin